

Effect of short-contact tar-derivates to UVB light therapy in *en plaque* psoriasis: a prospective single blind unicenter randomized clinical trial

Published: 07-05-2009

Last updated: 05-05-2024

We expect faster clearance of psoriatic lesions with the use of short-contact, local tar application during UVB-therapy, which will result in a lower cumulative UVB dosage.

Ethical review	Approved WMO
Status	Will not start
Health condition type	Epidermal and dermal conditions
Study type	Interventional

Summary

ID

NL-OMON32958

Source

ToetsingOnline

Brief title

Effect of short-contact tar to UVB light therapy in *en plaque* psoriasis

Condition

- Epidermal and dermal conditions

Synonym

psoriasis

Research involving

Human

Sponsors and support

Primary sponsor: Amphia Ziekenhuis

Source(s) of monetary or material Support: maatschap dermatologie;amphia ziekenhuis

Intervention

Keyword: □ Psoriasis, □ Tar application, □ UVB lighttherapy

Outcome measures

Primary outcome

The amount of UVB sessions needed until clearance of psoriatic lesions

Secondary outcome

the amount of joules needed untill clearance

Clearance of psoriasis after the full treatment period

Time until exacerbation after therapy

Quality of life

Monitoring of subjective complaints and side effects

Study description

Background summary

The idea of combining tar with light-therapy is almost a century old. Previously, tar has been used extensively all over the body. We would like to investigate the use of short contact, local tar application on psoriatic lesions during UVB-therapy.

Study objective

We expect faster clearance of psoriatic lesions with the use of short-contact, local tar application during UVB-therapy, which will result in a lower cumulative UVB dosage.

Study design

A prospective single blind randomized clinical trial

Intervention

application of coaltar solution or placebo

Study burden and risks

There will be short contact with a coaltar solution. The side effects of coaltar are little. There will be a very less extra time taken of the patients.

Contacts

Public

Amphia Ziekenhuis

molengracht 21
4818 CK Breda
NL

Scientific

Amphia Ziekenhuis

molengracht 21
4818 CK Breda
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Psoriasis vulgaris

Exclusion criteria

contraindications of UVB-therapy or tar application

Study design

Design

Study phase:	4
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Single blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL	
Recruitment status:	Will not start
Enrollment:	90
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	coaltarsolution
Generic name:	liquor carbonis detergens
Registration:	Yes - NL intended use

Ethics review

Approved WMO	
Date:	07-05-2009
Application type:	First submission

Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)
Approved WMO	
Date:	25-06-2010
Application type:	First submission
Review commission:	MEC-U: Medical Research Ethics Committees United (Nieuwegein)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2009-010863-18-NL
CCMO	NL26548.101.09